Sentiment Summary
Recent Events
The U.S. Office of Management and Budget (OMB) is scheduled to publish a full list of 'biotechnology companies of concern' (BCCs) by December 18, 2026, under the BIOSECURE Act; High importance is justified by the potential for severe regulatory risk causing a >10% price impact scheduled.
Ex-dividend date on June 16, 2026, for the 2025 final cash dividend of RMB 14.3 per 10 shares, with payment on July 13, 2026, scheduled. This consistent dividend payout is estimated to have a minor positive impact on investor sentiment.
Ex-dividend date for a proposed final dividend of HK$0.169 per share for the year ended December 31, 2025, on 2026-06-12 scheduled. Low importance as dividend ex-dates typically result in minor price adjustments.
Annual General Meeting scheduled for June 2, 2026, to vote on the 2025 profit distribution plan, a final dividend of RMB 1.26 per 10 shares, and a general mandate for the board to repurchase H-shares. Routine AGM and dividend announcement are likely to cause a price impact of 1% or more, scheduled.
GRAIL to present additional data from the NHS-Galleri trial at the 2026 ASCO Annual Meeting on May 30, 2026, scheduled. High importance estimated as clinical data is a key valuation driver.
Ex-dividend date for the final FY2025 dividend of HK$1.08 per share is scheduled for May 15, 2026.
Ex-dividend date on May 13, 2026, for the 2025 final cash dividend of RMB 1.57927 per share (RMB 15.7927 per 10 shares); low impact estimated as price typically adjusts by the dividend amount, scheduled.
The company will present at the BofA Securities 2026 Health Care Conference on May 12, 2026, scheduled. Investor conferences provide strategic updates (est. >1% impact).
First quarter 2026 financial results are scheduled to be released after market close on May 7, 2026. High importance is estimated due to the potential for significant price impact based on performance and outlook, scheduled.
Caris Life Sciences will report its first quarter 2026 financial results on May 7, 2026, scheduled. Earnings releases typically drive significant market volatility (est. >5% impact).
First quarter 2026 financial results and conference call are scheduled for after market close on May 7, 2026. Earnings releases typically result in significant market volatility, often exceeding 5% price impact, scheduled.
Q1 2026 earnings release is scheduled. Earnings announcements typically result in >5% price impact, scheduled.
First quarter 2026 financial results and conference call scheduled. Low impact is estimated as previous date announcements saw negative price movement, scheduled.
First quarter 2026 financial results and conference call scheduled.
GRAIL to announce first quarter 2026 financial results on May 5, 2026, scheduled. High importance estimated due to potential for high volatility following previous earnings reports.
Veracyte is scheduled to release its financial results for the first quarter of 2026 after the market close on May 5, 2026, with a conference call to follow; high impact is estimated based on historical earnings volatility, scheduled
First quarter 2026 financial results and conference call. Market impact estimated at Medium based on the typical importance of earnings releases, scheduled.
Scheduled to report Q2 2026 financial results on May 4, 2026; analysts forecast revenue of approximately $107.7M and an EPS of around -$0.53. Medium importance estimated due to typical earnings volatility, scheduled.
GeneDx is scheduled to release its Q1 2026 financial results after the market closes on May 4, 2026. Medium importance is assigned as earnings releases typically drive significant volatility. Analysts forecast earnings per share of ($0.06) and revenue of $112.45 million, estimated.
Illumina is scheduled to release its Q1 2026 financial results after the market close on April 30, 2026, followed by a conference call; high importance estimated due to potential for significant price movement following the earnings call scheduled
Scheduled release of Q1 2026 earnings on April 29, 2026, reporting a net profit of CNY 1.837 billion (616.34% increase). This significant turnaround is expected to drive a price impact of >=10%, expected.
Announced Q1 2026 results with revenue of RMB 316 million (+10.02% YoY) and net profit of RMB 238 million (+479.67% YoY), primarily due to an increase in gains from fair value changes of biological assets.
Announced on 2026-04-29 that its self-developed Class 1 new drug, HS-10522 tablets, received two clinical trial approvals from China's NMPA for treating uncontrolled hypertension and primary aldosteronism. Medium importance is assigned as clinical approvals for new drugs typically impact price by >=5%.
Announced on 2026-04-29 that its B7-H3 targeted ADC, HS-20093, was granted Breakthrough Therapy Designation by China's NMPA for treating advanced castration-resistant prostate cancer. Medium importance is assigned as Breakthrough Therapy Designation is a significant milestone likely impacting price by >=5%.
Announced the first patient enrollment in the Phase III registrational clinical trial of Orelabrutinib for Systemic Lupus Erythematosus (SLE) on 2026-04-29. Medium importance estimated as this key clinical milestone is likely to cause ≥5% price impact.
On April 29, 2026, the company announced the publication of a peer-reviewed study validating an AI-derived signature to predict temozolomide benefit in glioblastoma patients. Scientific validation supports clinical utility (est. >1% impact).
Announced Q1 2026 results, with net profit attributable to shareholders of RMB 49.04 million, a 70.36% decrease year-over-year, while revenue increased by 15.17% to RMB 1.801 billion. Significant profit decline is likely to cause a price impact of 10% or more, expected.
Q1 2026 results release on April 28, 2026, reporting a 6.93% YoY increase in revenue and a 13.87% YoY increase in net profit. Medium importance estimated due to significant profit growth likely impacting price by over 5%. Expected.
On 2026-04-28, announced Q1 2026 results with revenue of CNY 3.58 billion (+15.5% YoY) and net profit of CNY 335 million (+9.8% YoY). New orders grew over 30% YoY.
FDA briefing documents released on April 28, 2026, raised concerns about the trial design for AstraZeneca's camizestrant, which uses Guardant's G360 test. The news led to a stock price decline of approximately 5%.
Veracyte announced new data from over 15 studies at the 2026 American Urological Association (AUA) Annual Meeting, highlighting the clinical utility of its Decipher Prostate and Decipher Bladder tests.
Subsidiary clinical trial approval for SHR-2173 (myasthenia gravis) on April 28, 2026; low importance reflects expected >1% price impact. scheduled
Announced the repurchase of 2.066 million shares for HK$4.96 million on April 28, 2026, as part of its shareholder return program.
The Board of Directors resolved on 2026-04-28 to terminate the post-IPO restricted share unit (RSU) plan and proposed the adoption of a new 2026 Share Plan, subject to shareholder approval. Low importance is assigned as administrative share plan changes typically have >=1% price impact.
On 2026-04-28, announced proposal to change the number of board members from nine to eight and revise the Articles of Association, subject to shareholder approval.
JD Health is scheduled to announce a partnership with China Resources Sanjiu on April 28, 2026; this program is estimated to cause a >1% price impact, scheduled.
Announced Q1 2026 results on April 27, 2026, reporting a 45.1% YoY increase in revenue to RMB 726 million and a significant 91.2% reduction in net loss to RMB 20.56 million. The company achieved a net profit of RMB 43.44 million after excluding share-based payment expenses.
Announced Q1 2026 results on April 27, 2026, reporting a 28.8% YoY increase in revenue to RMB 12.44 billion and a 71.7% YoY increase in adjusted non-IFRS net profit to RMB 4.60 billion, beating expectations; high impact estimated due to significant profit growth, expected.
Biocytogen released its first-quarter 2026 report on 2026-04-27, showing revenue of about RMB 433.1 million and net profit attributable to shareholders of about RMB 104.0 million versus a loss a year earlier; likely medium positive due to the clear quarterly turnaround.
Q1 2026 results release scheduled for 2026-04-27. Analysts forecast revenue to increase 16.91% YoY to RMB 1.80 billion, but net profit to decrease 6.82% YoY to RMB 304 million. Importance is Medium as the profit decline is estimated to cause a 5-10% price impact, estimated.
Announced on 2026-04-27 that study results for Mesutoclax and Orelabrutinib were accepted for the 2026 ASCO Annual Meeting, with Mesutoclax selected for oral presentation. Medium importance estimated as an oral presentation at a major conference is likely to cause ≥5% price impact.
Strategic cooperation MOU with UAE-based Arcera Life Sciences on April 27, 2026, for licensing and neuroscience innovation. Low importance estimated as MOUs typically have less than 5% price impact. Scheduled.
Presented positive preliminary clinical results for multiple pipeline candidates at the 2026 AACR Annual Meeting, including the PD-1/VEGF bispecific antibody JS207 for liver and colorectal cancer, and the EGFR/HER3 bispecific ADC JS212 for solid tumors.
Shares fell 5.4% on April 25, 2026, after key industry peer Thermo Fisher Scientific reported weaker-than-expected core organic revenue growth, sparking concerns about a broader slowdown in the life sciences sector.
Granted 15.39 million restricted share units (0.87% of total shares) on 2026-04-24 under the 2023 Equity Incentive Plan. Low importance estimated as the minor dilution is likely to cause ≥1% price impact.